Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone
BA/BE studies are needed by regulations to guarantee remedial proportionality between a pharmaceutically comparable test item and a reference item. BA/BE studies are finished Early and late clinical trial definitions, Formulations utilized as a part of clinical trial and steadiness studies. Everybody has more heaped on their plate than any time in recent remembrance, and numerous consultant discover themselves always re-organizing their work exercises.
Bioavailability (BA) is defined as the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
Bioequivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.
Related Journals of BA/BE Studies
Journal of Bioequivalence & Bioavailability, MOJ Bioequivalence & Bioavailability, Clinical & Experimental Pharmacology, Chemical Speciation & Bioavailability, Indian Journal of Pharmaceutical Research, International Journal of BioAnalytical Methods & BioEquivalence Studies, Bioanalytical Methods & Bioequivalence Studies, Journal for Clinical Studies, Enliven: Biosimilars and Bioavailablity, Pharmaceutical Regulatory Affairs: Open Access, Journal of Molecular Pharmaceutics & Organic Process Research.